Table 5.

Relationship between the incidence of the primary endpoint and the TyG index expressed as a categorical variable

Variables	Univariate analysis HR (95% CI)	P value	Multivariate analysis HR (95% CI)	P-value
TyG index tertiles
T1	Reference		Reference
T2	1.74 (1.17–2.57)	0.006	1.60 (1.06–2.40)	0.025
T3	2.27 (1.56–3.32)	< 0.001	2.15 (1.44–3.22)	< 0.001
Age	1.01 (0.99–1.02)	0.458	0.99 (0.97–1.004)	0.138
BMI	0.98 (0.94–1.02)	0.300	0.97 (0.92–1.01)	0.166
DBP	0.98 (0.96–0.99)	0.001	0.99 (0.97–1.00)	0.048
HDL-C	0.98 (0.96–1.00)	0.014	0.98 (0.96–1.00)	0.042
Glycosylated haemoglobin	1.05 (0.94–1.18)	0.387	0.93 (0.82–1.06)	0.307
Male sex	0.92 (0.67–1.26)	0.603	0.68 (0.44–1.04)	0.077
Current smoking	0.94 (0.70–1.27)	0.699	1.02 (0.71–1.46)	0.918
Daily drinking	1.01 (0.62–1.65)	0.957	1.30 (0.77–2.18)	0.330
Previous MI	1.52 (1.11–2.09)	0.009	0.88 (0.61–1.27)	0.500
Past PCI	1.79 (1.33–2.41)	< 0.001	1.72 (1.17–2.53)	0.006
PAD	2.82 (2.05–3.87)	< 0.001	2.22 (1.52–3.24)	< 0.001
CKD	1.70 (1.07–2.70)	0.025	1.46 (0.85–2.52)	0.172
Cardiac failure	2.27 (1.52–3.40)	< 0.001	1.59 (1.00–2.52)	0.049
Insulin at discharge	1.39 (1.04–1.87)	0.025	0.95 (0.67–1.36)	0.797
Metformin at discharge	1.12 (0.76–1.63)	0.568	1.08 (0.72–1.62)	0.707
Alpha-glucosidase inhibitors at discharge	0.89 (0.66–1.21)	0.457	0.76 (0.55–1.06)	0.104
Sulfonylurea at discharge	0.89 (0.64–1.26)	0.524	0.95 (0.65–1.38)	0.784
Dipeptidyl peptidase 4 inhibitors at discharge	1.34 (0.50–3.60)	0.566	1.24 (0.44–3.48)	0.685
CAD severity
One-vessel disease	Reference		Reference
Two-vessel disease	2.08 (0.87–5.01)	0.101	1.30 (0.52–3.24)	0.579
LM/three-vessel disease	4.32 (1.91–9.76)	< 0.001	2.16 (0.91–5.13)	0.079
Lesions > 20 mm long	2.07 (1.51–2.84)	< 0.001	1.59 (1.13–2.23)	0.008
DCB use	2.07 (1.33–3.23)	0.001	1.23 (0.73–2.08)	0.430
Complete revascularization	0.46 (0.35–0.62)	< 0.001	0.63 (0.46–0.86)	0.004

Abbreviations as in Tables 1 and 2